Drugmaker Novo headed for EU approval for Catalent deal
Novo Holdings, the parent of Ozempic maker Novo Nordisk, appears on track to obtain unconditional EU approval for its $16.5 billion acquisition of US contract drugmaker Catalent, as the parties haven't...To view the full article, register now.
Already a subscriber? Click here to view full article